Evgen Pharma backs King's College London and British Heart Foundation research collaboration

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Evgen Pharma, a clinical stage drug development company, announced its support for a new research collaboration between King's College London and the British Heart Foundation investigating how the company's breast cancer drug can enhance neurovascular protection.

'Evgen will supply SFX-01 to the project and has the right to negotiate a licence over any resultant intellectual property, on fair and reasonable preferential terms,' the company said. 'If successful, the research will provide further insight into how SFX-01 mediates upregulation of Nrf2 in the blood-brain barrier endothelium, thereby enhancing neurovascular protection.'

This work will build on the existing collaboration between Evgen and King's. The collaboration had shown 'great promise for SFX-01 in both stroke and potentially wider neuropsychiatric complication,' Evgen added,

At 8:00am: (LON:EVG) Evgen Pharma Plc share price was 0p at 17.88p